Talphera, Inc. (NASDAQ:TLPH) Short Interest Update

Talphera, Inc. (NASDAQ:TLPH) saw a significant growth in short interest in April. As of April 15th, there was short interest totalling 184,900 shares, a growth of 166.8% from the March 31st total of 69,300 shares. Based on an average trading volume of 56,000 shares, the short-interest ratio is presently 3.3 days. Approximately 1.1% of the company’s shares are short sold.

Talphera Stock Performance

Shares of TLPH stock traded up $0.01 on Monday, hitting $0.50. The stock had a trading volume of 2,906 shares, compared to its average volume of 75,026. The stock’s 50 day moving average is $0.54 and its 200-day moving average is $0.66. The firm has a market capitalization of $8.53 million, a price-to-earnings ratio of -0.70 and a beta of 0.19. Talphera has a 52-week low of $0.45 and a 52-week high of $1.27.

Talphera (NASDAQ:TLPH) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.07) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.21) by $0.14. Equities analysts expect that Talphera will post -0.64 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently weighed in on TLPH shares. Rodman & Renshaw initiated coverage on shares of Talphera in a report on Tuesday, January 28th. They set a “buy” rating and a $4.00 target price on the stock. HC Wainwright restated a “buy” rating and set a $6.00 price objective on shares of Talphera in a research note on Tuesday, April 1st. Finally, RODMAN&RENSHAW upgraded Talphera to a “strong-buy” rating in a research note on Tuesday, January 28th.

Talphera Company Profile

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.